Ette EI - Search Results

1

A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitro.

Bisaso KR, Mukonzo JK, Ette EI. Bisaso KR, et al. Among authors: ette ei. In Silico Pharmacol. 2023 Oct 27;11(1):31. doi: 10.1007/s40203-023-00168-y. eCollection 2023. In Silico Pharmacol. 2023. PMID: 37899968

2

The new big is small: Leveraging knowledge from small trials for rare disease drug development: Blarcamesine for Rett syndrome.

Ette EI, Fadiran EO, Missling C, Hammond E. Ette EI, et al. Br J Clin Pharmacol. 2023 Jul 10. doi: 10.1111/bcp.15843. Online ahead of print. Br J Clin Pharmacol. 2023. PMID: 37429704 Review.

3

Population-Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease.

Fadiran EO, Hammond E, Tran J, Missling CU, Ette E. Fadiran EO, et al. Clin Pharmacol Drug Dev. 2024 Jan;13(1):21-31. doi: 10.1002/cpdd.1323. Epub 2023 Dec 10. Clin Pharmacol Drug Dev. 2024. PMID: 38073274

4

Plasma concentration and eGFR in preterm and term neonates receiving gentamicin or successive amikacin therapy.

Singu BS, Ndeunyema MN, Ette EI, Pieper CH, Verbeeck RK. Singu BS, et al. Among authors: ette ei. BMC Pediatr. 2023 Jan 16;23(1):24. doi: 10.1186/s12887-023-03834-4. BMC Pediatr. 2023. PMID: 36647065 Free PMC article.

5

Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System Toxicity.

Bisaso KS, Bisaso KR, Mukonzo JK, Ette EI. Bisaso KS, et al. Among authors: ette ei. J Clin Pharmacol. 2020 Jun;60(6):711-721. doi: 10.1002/jcph.1570. Epub 2020 Feb 25. J Clin Pharmacol. 2020. PMID: 32096561

6

Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome.

Tolbert D, Chu HM, Ette EI. Tolbert D, et al. Among authors: ette ei. Epilepsy Res. 2019 Nov;157:106182. doi: 10.1016/j.eplepsyres.2019.106182. Epub 2019 Jul 31. Epilepsy Res. 2019. PMID: 31563030 Free article.

7

Transition modeling of neuropsychiatric impairment in HIV.

Bisaso KR, Mukonzo JK, Ette EI. Bisaso KR, et al. Among authors: ette ei. Comput Biol Med. 2016 Jun 1;73:141-6. doi: 10.1016/j.compbiomed.2016.04.011. Epub 2016 Apr 15. Comput Biol Med. 2016. PMID: 27107677

8

Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions.

Tolbert D, Bekersky I, Chu HM, Ette EI. Tolbert D, et al. Among authors: ette ei. J Clin Pharmacol. 2016 Mar;56(3):365-74. doi: 10.1002/jcph.603. Epub 2015 Sep 29. J Clin Pharmacol. 2016. PMID: 26224203 Clinical Trial.

9

An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics.

Tolbert D, Bekersky I, Chu HM, Ette EI. Tolbert D, et al. Among authors: ette ei. J Clin Pharmacol. 2016 Feb;56(2):213-22. doi: 10.1002/jcph.586. Epub 2015 Sep 7. J Clin Pharmacol. 2016. PMID: 26139309

10

Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy.

Bisaso KR, Mukonzo JK, Ette EI. Bisaso KR, et al. Among authors: ette ei. J Clin Pharmacol. 2015 Nov;55(11):1229-35. doi: 10.1002/jcph.533. Epub 2015 Jun 19. J Clin Pharmacol. 2015. PMID: 25939460

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

48 results

Search Page